文献速递前列腺癌

2019年Briganti列线图外部验证:识别前列腺癌扩大盆腔淋巴结清扫候选者

External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection.
PubMed 文献 · Eur Urol · 2020-04-05

本研究在6中心487例经MRI靶向联合系统穿刺确诊并接受根治性前列腺切除术及扩大盆腔淋巴结清扫的前列腺癌患者中,首次多机构外部验证2019年Briganti列线图预测淋巴结侵犯风险。结果显示该列线图AUC为79%,在预测概率≤35%范围内校准良好,决策曲线分析显示在≤30%阈值概率下净获益优于2012/2017版列线图及MSKCC风险计算器。以7%为 cutoff 可避免56%的ePLND且仅漏诊2.6%的LNI。

要点

  • 2019年Briganti列线图外部验证AUC达79%,判别能力优于既往工具。
  • 在临床相关预测概率范围内校准良好,高概率区间存在一定校准偏差。
  • 7%阈值下可避免56%扩大盆腔淋巴结清扫,仅漏诊2.6%淋巴结侵犯。

核心结论

  • 2019年Briganti列线图在MRI靶向穿刺确诊的前列腺癌患者中外部验证确认最高AUC、更好校准及最高净获益,应被用于筛选扩大盆腔淋巴结清扫候选者。

研究设计与样本

  • 多中心外部验证研究,纳入6个中心共487例经MRI靶向联合系统穿刺确诊、接受根治性前列腺切除术及解剖学定义扩大盆腔淋巴结清扫的前列腺癌患者。
  • 通过校准、判别和决策曲线分析评估2019年Briganti列线图预测淋巴结侵犯风险的外部有效性。

主要发现

  • 最终病理显示38例(8%)存在淋巴结侵犯,中位切除淋巴结数为18枚(四分位距14-24)。
  • 2019年Briganti列线图外部验证的受试者工作特征曲线下面积(AUC)为79%。
  • 预测概率>35%时存在一定校准偏差,但该范围超出临床相关区间。
  • 决策曲线分析显示在淋巴结侵犯阈值概率≤30%时,2019年Briganti列线图改善临床风险预测。
  • 以7%为 cutoff 时,273例(56%)扩大盆腔淋巴结清扫可被避免,仅2.6%的淋巴结侵犯被漏诊。

关键数值与推荐

  • 2019年Briganti列线图外部验证AUC为79%,2012版为75%,2017版为65%,MSKCC风险计算器为74%。
  • 在预测概率>35%时存在校准偏差,但该范围超出临床相关区间。
  • 在淋巴结侵犯阈值概率≤30%时,2019年Briganti列线图改善临床风险预测。
  • 以7%为 cutoff,56%(273/487)的扩大盆腔淋巴结清扫可被避免,仅2.6%的淋巴结侵犯被漏诊。

临床怎么用

  • 对于MRI靶向穿刺确诊的前列腺癌患者,应采用2019年Briganti列线图评估淋巴结侵犯风险以筛选扩大盆腔淋巴结清扫候选者。
  • 该列线图在临床相关预测概率范围内校准良好且净获益最高,优于2012/2017版列线图及MSKCC风险计算器。
  • 以7%为阈值可安全避免超过半数扩大盆腔淋巴结清扫,漏诊淋巴结侵犯风险低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2019 Briganti nomogram was developed to calculate the risk of lymph node invasion (LNI) and identify prostate cancer (PCa) patients diagnosed with magnetic resonance imaging (MRI)-targeted biopsy who should be considered for an extended pelvic lymph node dissection (ePLND). Since its implementation is still limited by lack of a formal external validation, we aimed to validate this tool in a large contemporary cohort. We identified 487 patients diagnosed using MRI-targeted with concomitant systematic biopsy who underwent radical prostatectomy (RP) and an anatomically defined ePLND at six centers. The external validity of the 2019 Briganti nomogram for estimating LNI risk was assessed via calibration, discrimination, and decision curve analyses (DCAs). A total of 38 (8%) patients had LNI at final pathology. The median number of nodes removed was 18 (interquartile range 14-24). On external validation, the 2019 Briganti nomogram had an area under the receiver operating characteristic curve (AUC) of 79%. Although there was some miscalibration, this was at predicted probabilities >35% and therefore outside the clinically relevant range. DCA demonstrated that the 2019 Briganti nomogram improved clinical risk prediction against LNI threshold probabilities of ≤30%. For a 7% cutoff, 273 (56%) ePLNDs would be spared and only 2.6% LNIs would be missed. The 2019 Briganti nomogram was characterized by higher AUC compared to the 2012 and 2017 Briganti nomograms and the Memorial Sloan Kettering Cancer Center risk calculator (79% vs 75% vs 65% vs 74%) and demonstrated the highest net benefit on DCA. This first multi-institutional validation of the 2019 Briganti nomogram in predicting LNI in PCa patients diagnosed with MRI-targeted biopsy confirms the highest AUC, better calibration and the highest net benefit compared with available tools and should be adopted to identify candidates for ePLND among men diagnosed with MRI-targeted biopsy. PATIENT SUMMARY: We performed the first multi-institutional validation of the first nomogram predicting lymph node invasion specifically developed using data from prostate cancer patients diagnosed with magnetic resonance imaging (MRI)-targeted biopsy. This nomogram exhibited excellent characteristics on external validation compared with available tools and should be adopted to identify candidates for extended pelvic lymph node dissection among men diagnosed with MRI-targeted biopsy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Gandaglia G, Martini A, Ploussard G, et al. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. Eur Urol. 2020. PMID: 32268944. doi:10.1016/j.eururo.2020.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。